Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Product/Service

EVER Pharma Launches the User-friendly D-mine® Pump Generated Report "DATA-mine®" to Enhance the Therapy Management of Parkinson's Patients on Apomorphine


After successfully launching the D-mine® Pump, a micro infusion device designed to provide precise continuous subcutaneous drug delivery for PD patients, the product family has been extended to include a comprehensive data history readout.

EVER Pharma, a specialist in neurology and specialty pharmaceuticals, offers a complete therapy package for PD patients with Dacepton® (Dopaceptin®, Apomorphine hydrochloride), D-mine® Pump, D-mine® Pen and now the DATA-mine® REPORT, a tool to read out the data of the D-mine® Pump.

Through this tool the D-mine® Pump history file can be easily transformed into a handy report in PDF format, on Windows or macOS devices allowing Healthcare Professionals to navigate through the various parameters of the infusion therapy like dosing, flow rates, and time settings in easy-to-read tables and graphs and adapt it accordingly.

"With the DATA-mine® REPORT, we continue to optimize our product offering by ensuring the best possible therapy management of Parkinson's patients on Apomorphine and facilitating the follow up of the Healthcare Professional", explains Georges Kahwati, General Manager at EVER Pharma GmbH.

For more information please visit www.d-minecare.com.

About EVER Pharma GmbH
EVER Pharma is a fully integrated specialty pharmaceuticals company focused on the research, development, production and commercialization of products in the areas of neurology, critical care, anesthesia and oncology.

From global headquarters in Austria it runs a dynamic operation providing innovative therapies and value-added formulations aimed at enhancing patient and healthcare professional's lives through improved safety and convenience.

The products are developed and manufactured at EU GMP certified facilities in Austria and Germany. The technical operations are highly specialized in the production of complex injectables including high potency substances, crystal suspensions, oily solutions and controlled substances in vials, pre-filled syringes, cartridges, ampoules and implants. EVER markets its products in more than 80 countries around the world through 30 international affiliated companies and strategic partners.


These press releases may also interest you

at 18:30
Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards. "This product, along with our other innovations,...

at 18:23
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...

at 17:55
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...

at 17:20
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...

at 17:00
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...



News published on and distributed by: